@oriro/orirocli 0.1.8 → 0.1.11

package/skills/industry/industry-pharma/SKILL.md

@@ -1,69 +1,69 @@
----
-watermark: ORIRO
-disable-model-invocation: true
-name: industry-pharma
-provider: ORIRO.ai
-copyright: Copyright (c) 2026 ORIRO.ai
-description: >
-
-
-
-
-
-
-
-
-
-  Pharmaceutical industry — drug development, clinical trials, regulatory pathway, IP, and pharma business model.
-  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
----
-
-# Pharmaceutical Industry
-
-## Drug development process
-
-### Discovery and preclinical (5-10 years)
-
-Target identification: Which biological target (protein, receptor) to address?
-Hit/lead identification: Screen millions of compounds for activity at target.
-Lead optimization: Improve potency, selectivity, safety, and bioavailability.
-Preclinical testing: Animal studies for safety and preliminary efficacy.
-IND (Investigational New Drug) application filed with FDA.
-
-### Clinical trials (6-12 years)
-
-**Phase I:** First in humans. ~20-100 healthy volunteers. Safety, dosing, pharmacokinetics. Success rate: ~70%.
-**Phase II:** Small patient population (~100-500). Preliminary efficacy, optimal dose, safety. Success rate: ~40%.
-**Phase III:** Large randomized controlled trial (~1,000-3,000+ patients). Efficacy vs. standard of care. Success rate: ~65%.
-**Overall Phase I-III success:** Only ~12% of drugs that enter clinical trials make it to approval.
-
-### FDA review
-
-**NDA/BLA submission:** New Drug Application (small molecules) or Biologics License Application (biologics).
-PDUFA date: Review deadline (typically 12 months, 6 months for priority review).
-Advisory committee: External experts advise FDA (non-binding).
-**Priority review, Breakthrough therapy, Accelerated approval, Fast track:** Expedited pathways for serious conditions with unmet needs.
-
-## Key regulatory concepts
-
-**Bioequivalence:** Generic drugs must demonstrate equivalent absorption to brand drug. 80-125% CI on pharmacokinetic parameters.
-**505(b)(2) pathway:** Uses published data/prior approvals for reformulations or new indications.
-**Orphan drug designation:** For diseases affecting < 200,000 US patients. Benefits: 7-year exclusivity, fee waivers, tax credits.
-**Post-market surveillance:** Phase IV studies and safety monitoring after approval.
-
-## Intellectual property
-
-**Patent term:** 20 years from filing date. Effective patent life reduced by development time.
-**Data exclusivity:** Separate from patents. FDA won't approve generics for 5 years (NCE), 3 years (new indication), 12 years (biologics).
-**Patent cliff:** When key patents expire, generic/biosimilar competition can drop prices 80-90%.
-**Evergreening:** Extending patent protection through formulation changes, new indications, pediatric exclusivity.
-
-## Business model
-
-**High-risk, high-reward:** Average R&D cost per approved drug: $1-3 billion. Only 1 in 10,000 screened compounds reaches market.
-**Pricing power:** For novel drugs with no competition and significant clinical benefit, manufacturers have significant pricing power in US market (not in most other countries).
-**US vs. international pricing:** US prices often 3-10× higher than other developed countries due to lack of centralized price negotiation.
-**Generic market:** ~90% of US prescriptions by volume are generics. ~20% by spending.
-**Biosimilars:** Generic equivalents to biologics. More complex, more expensive to develop than small molecule generics.
-
-Sources: FDA (fda.gov — free drug approvals, guidance documents), Drugs@FDA database (free), PhRMA (phrma.org — free industry data), EvaluatePharma (limited free data), STAT News (free healthcare journalism)
+---
+watermark: ORIRO
+disable-model-invocation: true
+name: industry-pharma
+provider: ORIRO.ai
+copyright: Copyright (c) 2026 ORIRO.ai
+description: >
+
+
+
+
+
+
+
+
+
+  Pharmaceutical industry — drug development, clinical trials, regulatory pathway, IP, and pharma business model.
+  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
+---
+
+# Pharmaceutical Industry
+
+## Drug development process
+
+### Discovery and preclinical (5-10 years)
+
+Target identification: Which biological target (protein, receptor) to address?
+Hit/lead identification: Screen millions of compounds for activity at target.
+Lead optimization: Improve potency, selectivity, safety, and bioavailability.
+Preclinical testing: Animal studies for safety and preliminary efficacy.
+IND (Investigational New Drug) application filed with FDA.
+
+### Clinical trials (6-12 years)
+
+**Phase I:** First in humans. ~20-100 healthy volunteers. Safety, dosing, pharmacokinetics. Success rate: ~70%.
+**Phase II:** Small patient population (~100-500). Preliminary efficacy, optimal dose, safety. Success rate: ~40%.
+**Phase III:** Large randomized controlled trial (~1,000-3,000+ patients). Efficacy vs. standard of care. Success rate: ~65%.
+**Overall Phase I-III success:** Only ~12% of drugs that enter clinical trials make it to approval.
+
+### FDA review
+
+**NDA/BLA submission:** New Drug Application (small molecules) or Biologics License Application (biologics).
+PDUFA date: Review deadline (typically 12 months, 6 months for priority review).
+Advisory committee: External experts advise FDA (non-binding).
+**Priority review, Breakthrough therapy, Accelerated approval, Fast track:** Expedited pathways for serious conditions with unmet needs.
+
+## Key regulatory concepts
+
+**Bioequivalence:** Generic drugs must demonstrate equivalent absorption to brand drug. 80-125% CI on pharmacokinetic parameters.
+**505(b)(2) pathway:** Uses published data/prior approvals for reformulations or new indications.
+**Orphan drug designation:** For diseases affecting < 200,000 US patients. Benefits: 7-year exclusivity, fee waivers, tax credits.
+**Post-market surveillance:** Phase IV studies and safety monitoring after approval.
+
+## Intellectual property
+
+**Patent term:** 20 years from filing date. Effective patent life reduced by development time.
+**Data exclusivity:** Separate from patents. FDA won't approve generics for 5 years (NCE), 3 years (new indication), 12 years (biologics).
+**Patent cliff:** When key patents expire, generic/biosimilar competition can drop prices 80-90%.
+**Evergreening:** Extending patent protection through formulation changes, new indications, pediatric exclusivity.
+
+## Business model
+
+**High-risk, high-reward:** Average R&D cost per approved drug: $1-3 billion. Only 1 in 10,000 screened compounds reaches market.
+**Pricing power:** For novel drugs with no competition and significant clinical benefit, manufacturers have significant pricing power in US market (not in most other countries).
+**US vs. international pricing:** US prices often 3-10× higher than other developed countries due to lack of centralized price negotiation.
+**Generic market:** ~90% of US prescriptions by volume are generics. ~20% by spending.
+**Biosimilars:** Generic equivalents to biologics. More complex, more expensive to develop than small molecule generics.
+
+Sources: FDA (fda.gov — free drug approvals, guidance documents), Drugs@FDA database (free), PhRMA (phrma.org — free industry data), EvaluatePharma (limited free data), STAT News (free healthcare journalism)

package/skills/industry/industry-real-estate/LICENSE

@@ -1,21 +1,21 @@
-MIT License
-
-Copyright (c) 2026 ORIRO.ai
-
-Permission is hereby granted, free of charge, to any person obtaining a copy
-of this software and associated documentation files (the "Software"), to deal
-in the Software without restriction, including without limitation the rights
-to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
-copies of the Software, and to permit persons to whom the Software is
-furnished to do so, subject to the following conditions:
-
-The above copyright notice and this permission notice shall be included in all
-copies or substantial portions of the Software.
-
-THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
-IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
-FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
-AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
-LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
-OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
-SOFTWARE.
+MIT License
+
+Copyright (c) 2026 ORIRO.ai
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.

package/skills/industry/industry-real-estate/SKILL.md

@@ -1,61 +1,61 @@
----
-watermark: ORIRO
-disable-model-invocation: true
-name: industry-real-estate
-provider: ORIRO.ai
-copyright: Copyright (c) 2026 ORIRO.ai
-description: >
-  Real estate industry — property development, brokerage, property management, commercial real estate, and market analysis.
-
-
-
-
-
-
-
-
-
-  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
----
-
-# Real Estate Industry
-
-## The development process
-
-1. **Site selection:** Feasibility analysis. Demographics, traffic, competition, zoning.
-2. **Due diligence:** Title search, environmental (Phase I/II), survey, geotechnical, building inspection.
-3. **Entitlement:** Zoning approvals, variances, permits. Often most time-consuming stage (months to years).
-4. **Financing:** Construction loan (typically 65-75% LTC), equity raise, permanent financing commitment.
-5. **Construction:** GC selection (bid or negotiate), subcontractors, draws against construction loan.
-6. **Lease-up/Sale:** Marketing, broker relationships, lease negotiation.
-7. **Stabilization/Exit:** Reaching target occupancy (typically 90-95%). Refinance or sale.
-
-## Commercial real estate asset classes
-
-**Office:** Urban/suburban, Class A/B/C. Vacancy elevated post-COVID. Work-from-home structural headwind.
-**Industrial/Logistics:** Warehouses, distribution centers, manufacturing. Strongest sector — e-commerce demand.
-**Retail:** Enclosed malls declining. Power centers, grocery-anchored centers more resilient. "Experiential" retail growing.
-**Multifamily:** Apartments. Recession-resilient. Rising rents in supply-constrained markets.
-**Hospitality:** Hotels. Highly cyclical. Brand affiliation and revenue management critical.
-**Self-storage:** Counter-cyclical, recession-resilient.
-**Data centers:** Fastest-growing sector. AI demand driving. Power and cooling intensive.
-**Life sciences:** Labs and research facilities. High-barrier supply; strong demand.
-
-## Key metrics
-
-**NOI (Net Operating Income):** Revenue - Operating Expenses (not debt service). Core income metric.
-**Cap rate:** NOI / Value. See finance-real-estate skill.
-**Gross Lease:** Landlord pays most operating expenses. Tenant pays base rent only.
-**NNN (Triple Net Lease):** Tenant pays rent + real estate taxes + insurance + maintenance. Landlord has minimal expenses.
-**WALT (Weighted Average Lease Term):** Remaining lease duration weighted by rent. Longer = more valuable to investors.
-**Vacancy rate vs. absorption:** Market-level metrics. Positive absorption = tenants taking more space than vacating.
-
-## Brokerage and transactions
-
-**Listing broker (seller's agent) vs. Buyer's broker:** Fiduciary duty to respective clients.
-**CAP rate vs. GRM:** Different approaches to valuing the same income property.
-**Letter of Intent (LOI):** Non-binding expression of intent. Establishes key terms before drafting purchase agreement.
-**Purchase and Sale Agreement (PSA):** Binding contract. Includes: price, deposit, due diligence period, contingencies.
-**1031 Exchange:** Tax deferral on investment property sale. Must identify replacement within 45 days, close within 180.
-
-Sources: CBRE research (free market reports), JLL Research (free), Urban Land Institute (uli.org — some free), CoStar (limited free), NAIOP commercial real estate association (free resources)
+---
+watermark: ORIRO
+disable-model-invocation: true
+name: industry-real-estate
+provider: ORIRO.ai
+copyright: Copyright (c) 2026 ORIRO.ai
+description: >
+  Real estate industry — property development, brokerage, property management, commercial real estate, and market analysis.
+
+
+
+
+
+
+
+
+
+  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
+---
+
+# Real Estate Industry
+
+## The development process
+
+1. **Site selection:** Feasibility analysis. Demographics, traffic, competition, zoning.
+2. **Due diligence:** Title search, environmental (Phase I/II), survey, geotechnical, building inspection.
+3. **Entitlement:** Zoning approvals, variances, permits. Often most time-consuming stage (months to years).
+4. **Financing:** Construction loan (typically 65-75% LTC), equity raise, permanent financing commitment.
+5. **Construction:** GC selection (bid or negotiate), subcontractors, draws against construction loan.
+6. **Lease-up/Sale:** Marketing, broker relationships, lease negotiation.
+7. **Stabilization/Exit:** Reaching target occupancy (typically 90-95%). Refinance or sale.
+
+## Commercial real estate asset classes
+
+**Office:** Urban/suburban, Class A/B/C. Vacancy elevated post-COVID. Work-from-home structural headwind.
+**Industrial/Logistics:** Warehouses, distribution centers, manufacturing. Strongest sector — e-commerce demand.
+**Retail:** Enclosed malls declining. Power centers, grocery-anchored centers more resilient. "Experiential" retail growing.
+**Multifamily:** Apartments. Recession-resilient. Rising rents in supply-constrained markets.
+**Hospitality:** Hotels. Highly cyclical. Brand affiliation and revenue management critical.
+**Self-storage:** Counter-cyclical, recession-resilient.
+**Data centers:** Fastest-growing sector. AI demand driving. Power and cooling intensive.
+**Life sciences:** Labs and research facilities. High-barrier supply; strong demand.
+
+## Key metrics
+
+**NOI (Net Operating Income):** Revenue - Operating Expenses (not debt service). Core income metric.
+**Cap rate:** NOI / Value. See finance-real-estate skill.
+**Gross Lease:** Landlord pays most operating expenses. Tenant pays base rent only.
+**NNN (Triple Net Lease):** Tenant pays rent + real estate taxes + insurance + maintenance. Landlord has minimal expenses.
+**WALT (Weighted Average Lease Term):** Remaining lease duration weighted by rent. Longer = more valuable to investors.
+**Vacancy rate vs. absorption:** Market-level metrics. Positive absorption = tenants taking more space than vacating.
+
+## Brokerage and transactions
+
+**Listing broker (seller's agent) vs. Buyer's broker:** Fiduciary duty to respective clients.
+**CAP rate vs. GRM:** Different approaches to valuing the same income property.
+**Letter of Intent (LOI):** Non-binding expression of intent. Establishes key terms before drafting purchase agreement.
+**Purchase and Sale Agreement (PSA):** Binding contract. Includes: price, deposit, due diligence period, contingencies.
+**1031 Exchange:** Tax deferral on investment property sale. Must identify replacement within 45 days, close within 180.
+
+Sources: CBRE research (free market reports), JLL Research (free), Urban Land Institute (uli.org — some free), CoStar (limited free), NAIOP commercial real estate association (free resources)

package/skills/industry/industry-sports/LICENSE

@@ -1,21 +1,21 @@
-MIT License
-
-Copyright (c) 2026 ORIRO.ai
-
-Permission is hereby granted, free of charge, to any person obtaining a copy
-of this software and associated documentation files (the "Software"), to deal
-in the Software without restriction, including without limitation the rights
-to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
-copies of the Software, and to permit persons to whom the Software is
-furnished to do so, subject to the following conditions:
-
-The above copyright notice and this permission notice shall be included in all
-copies or substantial portions of the Software.
-
-THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
-IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
-FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
-AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
-LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
-OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
-SOFTWARE.
+MIT License
+
+Copyright (c) 2026 ORIRO.ai
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.

package/skills/industry/industry-sports/SKILL.md

@@ -1,71 +1,71 @@
----
-watermark: ORIRO
-disable-model-invocation: true
-name: industry-sports
-provider: ORIRO.ai
-copyright: Copyright (c) 2026 ORIRO.ai
-description: >
-
-
-
-
-
-
-  Sports management — sports business, contracts, athlete management, sports science, and venue operations.
-
-
-
-  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
----
-
-# Sports Management
-
-## Sports business economics
-
-### Revenue streams (professional sports)
-
-**Media rights:** Often 50-70% of league revenue. NFL: ~$110B+ in TV deals. NBA, MLB, NHL: Significant TV/streaming rights.
-**Ticket sales:** Gate receipts. Suite/premium seating is disproportionately valuable.
-**Sponsorships:** Jersey patches, naming rights (stadium), presenting sponsors, official partners.
-**Merchandise/licensing:** Team-branded products. League-controlled licensing.
-**Venue:** Concerts, events when team not playing.
-**Expansion/franchise fees:** New teams paying into the league.
-
-### Player contracts and salary caps
-
-**Salary cap:** Maximum team payroll. Hard cap (NHL, NFL) vs. luxury tax soft cap (NBA, MLB).
-**Guaranteed vs. non-guaranteed:** NFL contracts mostly non-guaranteed; NBA mostly guaranteed.
-**Collective Bargaining Agreement (CBA):** Agreement between league and players' union governing all terms. Governs revenue split, salary caps, free agency, arbitration, discipline.
-**Arbitration (MLB):** Salary determined by arbitrator based on comparable players. Players typically eligible after 3 years.
-**Free agency:** After CBA-determined service time, can negotiate with any team.
-
-## Athlete representation
-
-### Agent's role
-
-Negotiate contracts, endorsements, appearance fees. Manage career.
-NFLPA/NBPA/MLBPA: Player associations certify agents.
-**Standard commission:** 3-5% of contracts, 10-20% of endorsements.
-**Fiduciary duty:** Agent must act in client's best interest. Conflicts of interest strictly regulated.
-
-### Sports science
-
-**Performance optimization:** Sports science staff (strength/conditioning, sports medicine, analytics).
-**Load management:** Monitoring training and competitive workload to prevent injury. GPS tracking, heart rate variability, sleep monitoring.
-**Biomechanics:** Video analysis of movement mechanics. Injury prevention and technique optimization.
-**Sports psychology:** Mental performance coaching. Visualization, focus techniques, pressure management.
-
-## Venue operations
-
-**Facility management:** Building systems, security, event operations.
-**Revenue maximization:** Concert bookings, private events, suites/hospitality packages.
-**Fan experience:** Food and beverage, technology (wifi, cashless payments, mobile ordering), wayfinding.
-**Sustainability:** LEED certification for venues, food waste reduction, renewable energy.
-
-## Sports media
-
-**Broadcast rights:** Local (regional sports networks) + national (network TV, streaming).
-**Cord-cutting impact:** RSN (Regional Sports Network) model under stress. Direct-to-consumer streaming migration.
-**Social media:** Teams generate significant content. Fan engagement platforms.
-
-Sources: Sports Business Journal (sportsbusinessjournal.com — limited free), SMRI Sports Management Research Institute, NASSM (nassm.com), league CBAs (often publicly available)
+---
+watermark: ORIRO
+disable-model-invocation: true
+name: industry-sports
+provider: ORIRO.ai
+copyright: Copyright (c) 2026 ORIRO.ai
+description: >
+
+
+
+
+
+
+  Sports management — sports business, contracts, athlete management, sports science, and venue operations.
+
+
+
+  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
+---
+
+# Sports Management
+
+## Sports business economics
+
+### Revenue streams (professional sports)
+
+**Media rights:** Often 50-70% of league revenue. NFL: ~$110B+ in TV deals. NBA, MLB, NHL: Significant TV/streaming rights.
+**Ticket sales:** Gate receipts. Suite/premium seating is disproportionately valuable.
+**Sponsorships:** Jersey patches, naming rights (stadium), presenting sponsors, official partners.
+**Merchandise/licensing:** Team-branded products. League-controlled licensing.
+**Venue:** Concerts, events when team not playing.
+**Expansion/franchise fees:** New teams paying into the league.
+
+### Player contracts and salary caps
+
+**Salary cap:** Maximum team payroll. Hard cap (NHL, NFL) vs. luxury tax soft cap (NBA, MLB).
+**Guaranteed vs. non-guaranteed:** NFL contracts mostly non-guaranteed; NBA mostly guaranteed.
+**Collective Bargaining Agreement (CBA):** Agreement between league and players' union governing all terms. Governs revenue split, salary caps, free agency, arbitration, discipline.
+**Arbitration (MLB):** Salary determined by arbitrator based on comparable players. Players typically eligible after 3 years.
+**Free agency:** After CBA-determined service time, can negotiate with any team.
+
+## Athlete representation
+
+### Agent's role
+
+Negotiate contracts, endorsements, appearance fees. Manage career.
+NFLPA/NBPA/MLBPA: Player associations certify agents.
+**Standard commission:** 3-5% of contracts, 10-20% of endorsements.
+**Fiduciary duty:** Agent must act in client's best interest. Conflicts of interest strictly regulated.
+
+### Sports science
+
+**Performance optimization:** Sports science staff (strength/conditioning, sports medicine, analytics).
+**Load management:** Monitoring training and competitive workload to prevent injury. GPS tracking, heart rate variability, sleep monitoring.
+**Biomechanics:** Video analysis of movement mechanics. Injury prevention and technique optimization.
+**Sports psychology:** Mental performance coaching. Visualization, focus techniques, pressure management.
+
+## Venue operations
+
+**Facility management:** Building systems, security, event operations.
+**Revenue maximization:** Concert bookings, private events, suites/hospitality packages.
+**Fan experience:** Food and beverage, technology (wifi, cashless payments, mobile ordering), wayfinding.
+**Sustainability:** LEED certification for venues, food waste reduction, renewable energy.
+
+## Sports media
+
+**Broadcast rights:** Local (regional sports networks) + national (network TV, streaming).
+**Cord-cutting impact:** RSN (Regional Sports Network) model under stress. Direct-to-consumer streaming migration.
+**Social media:** Teams generate significant content. Fan engagement platforms.
+
+Sources: Sports Business Journal (sportsbusinessjournal.com — limited free), SMRI Sports Management Research Institute, NASSM (nassm.com), league CBAs (often publicly available)

package/skills/industry/industry-tech-startup/LICENSE

@@ -1,21 +1,21 @@
-MIT License
-
-Copyright (c) 2026 ORIRO.ai
-
-Permission is hereby granted, free of charge, to any person obtaining a copy
-of this software and associated documentation files (the "Software"), to deal
-in the Software without restriction, including without limitation the rights
-to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
-copies of the Software, and to permit persons to whom the Software is
-furnished to do so, subject to the following conditions:
-
-The above copyright notice and this permission notice shall be included in all
-copies or substantial portions of the Software.
-
-THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
-IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
-FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
-AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
-LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
-OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
-SOFTWARE.
+MIT License
+
+Copyright (c) 2026 ORIRO.ai
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.